Extended Data Fig. 1: Consolidated Standards of Reporting Trials (CONSORT) diagram, which includes the 149 patients that consented to I-PREDICT.
From: Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
*Treated evaluable patients includes patients who received >10 d of treatment for drugs given on a daily basis (generally drugs given by mouth) or at least two doses of a drug normally given every two weeks or more frequently (the latter generally being intravenous drugs). Only patients whose treatment was reviewed and validated by data analysis lockdown are included. **One patient had inadequate tissue for NGS and declined biopsy; he was later reenrolled after he agreed to undergo biopsy. One treated patient who initially was believed to have prior therapy was found, after data lockdown analysis, to have not received the prior regimen.
